

18-JUN-2018 6:11
OPEN STUDIES IRB REPORT

Disease Site	Study	Study Name	Open Date	Number of Active Institutions	Number of Current IRBs
BREAST	S1207	Brst,Adj,Endocrine+/-Everolimus	03-SEP-13	461	234
	S1416	Brst, TNBC/BRCA, Cis+/- ABT-888	07-JUL-16	279	133
	S1418	Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	15-NOV-16	432	202
	A011106	Breast, Neoadj, ALTERNATE study	15-FEB-14	264	122
	A011401	Breast, adj, Stage II/III HER2-, weight loss	29-AUG-16	442	238
	A011502	Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	08-DEC-16	0	223
	A221405	Breast, ET interruption, Pregnancy Outcomes	15-OCT-15	0	64
	B55	Brst, Adj Olaparib for BRCA,TNBC	03-JUL-14	443	185
	E1Z11	Brst,Genetic Predictors of AIMSS	10-MAY-13	189	69
	E2112	Brst,Adv,Exemestane+/-Entinostat	02-JAN-14	296	165
	EA1151	Brst, Tomosynthesis Mammographic Screening	06-JUL-17	0	54
	NRGBR002	Brst, OMBC, II-III, SoC +/- SBRT and/or SA	24-DEC-14	0	135
	NRGBR003	Brst,Adj,TNBC,AC -> WP +/- Carbo	22-JAN-15	441	215
	CCD	S1415CD	TrACER CSF Standing Order Intervention for FN	01-SEP-16	27
S1417CD		Colorectal, Cost Cohort Study	13-MAY-16	202	56
A011104		Preoperative Breast MRI	21-FEB-14	172	57
A191402C		PROS, Testing Decision Aids for Minority Men	14-JUL-17	0	2
ERLYTX	S1609	Rare Tumor, Comb Nivo/Ipi	13-JAN-17	337	159
	A071102	GBM, adj TMZ +/- Veliparib	19-SEP-14	368	168
	A071401	Prog Meningiomas,SMO/AKT/NF2 Inhib	06-AUG-15	289	109
	ARST1321	NonRhabdo STS,Pazopanib (PAZNTIS)	16-MAY-14	258	122
	EAY131	MATCH	12-AUG-15	471	236
GI	S1613	mCRC, Adv/Met, TP vs CETIRI	09-OCT-17	0	119
	A021501	Adeno Panc,Borderline Resect,Chemo vs ChemoRT	01-DEC-16	0	89
	A021502	Colon, Stg III, Chemo +/- Atezol, ATOMIC	12-SEP-17	0	27
	EA2142	GI NEC, Adv G3, EP vs TMZ + CAP	06-NOV-15	182	74
	N1048	Rectal,LocalAdv,ChemoRT+/-FOLFOX	13-JAN-12	0	162
	NRGGI002	Rectal, Ph II, Sensitization using TNT	12-OCT-16	325	140
	NRGGI004	Colorectal, Stg IV, dMMR Immuno-Therapy	07-NOV-17	0	18
	R0848	Panc, Adj, Erlotinib v ChemoRT	01-MAR-14	0	137
GU	S1500	pRCC,Adv, Sunitinib vs MET inhib	05-APR-16	225	96
	S1602	Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	07-FEB-17	154	74
	S1605	Blad, BCG-Unresponsive NMIBC, Atezolizumab	07-FEB-17	160	71

**18-JUN-2018 6:11
OPEN STUDIES IRB REPORT**

Disease Site	Study	Study Name	Open Date	Number of Active Institutions	Number of Current IRBs
	A031102	GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	01-JUL-15	66	35
	A031501	Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs	21-SEP-17	0	14
	EA8143	RCC, HR, Surg +/- Nivolumab (PROSPER)	02-FEB-17	0	123
	NRGGU002	Pros, RT + ADT After RP +/- Adj Docetaxel	30-DEC-16	0	125
	R0924	Pros, NADT+WPRT vs. NADT+P&SV RT	07-JUL-11	0	175
LEUK	S1312	ALL, CD22+, REL/REF, Inotuzumab+CVP	01-APR-14	3	3
	S1612	AML/MDS, Age 60+, Aza/Novel Therapeutics	22-DEC-17	0	66
	E1910	BCR-ABL-neg, B ALL, Blinatumomab	23-DEC-13	168	87
	E2906	AML, Age 60+, Clo vs Dauno+Cy	24-FEB-11	138	72
	NHLBIMDS	LEUK, National MDS Study	05-APR-16	243	102
LUNG	S1400	SCCA,Adv, Biomarker Master	15-JUN-14	441	217
	S1400F	Non-Match: MEDI4736 + Tremelimumab	02-OCT-17	0	220
	S1400G	HRRD: Talazoparib (BMN 673)	07-FEB-17	438	217
	S1400K	c-Met: ABBV-399 (Process II)	05-FEB-18	0	204
	S1619	Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC	03-NOV-17	0	20
	A081105	ALCHEMIST1, EGFR mut, Erlotinib	02-JAN-14	0	254
	A151216	ALCHEMIST0 - screening	06-FEB-14	466	257
	C30610	SCLC, Thoracic RT	21-MAR-08	211	114
	E4512	ALCHEMIST2, ALK mut, Crizotinib	18-AUG-14	474	255
	EA5142	ALCHEMIST3, Non-match, Nivolumab	16-MAY-16	420	237
	NRGCC003	SCLC, PCI or HA-PCI	07-DEC-15	318	138
LYMPH	S1608	Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob	10-AUG-17	0	104
	A051301	ABC DLBCL, Auto HCT and Ibrutinib/Placebo	15-JUL-16	170	73
	EA4151	Lymph, AHCT +/-Ritux, MRD Neg	29-AUG-17	0	13
MELAN	S1320	Adv, BRAF mut, Inter v Contin	22-JUL-14	229	106
	S1512	Melan, Adv, Desmoplastic, MK-3475 (pembro)	20-OCT-16	75	39
	S1607	MELAN, Adv, T-VEC, MK-3475	02-OCT-17	0	19
	S1616	MELAN, Adv, Ipilimumab ± Nivolumab	17-JUL-17	0	93
	EA6134	Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	15-DEC-15	346	147
	EA6141	Melan, Adv, Nivolumab+Ipi ± Sargmostim	01-MAR-16	301	120
MMYEL	S1702	AL Amyloidosis, Relapsed, Isatuximab	08-MAR-18	0	41
	E1A11	MM, frontline, BLD vs CLD	22-NOV-13	307	131

**18-JUN-2018 6:11
OPEN STUDIES IRB REPORT**

<u>Disease Site</u>	<u>Study</u>	<u>Study Name</u>	<u>Open Date</u>	<u>Number of Active Institutions</u>	<u>Number of Current IRBs</u>	
OTHER	A091202	Sarc, Efatutazone vs Placebo, Unresect ,Lipo	02-SEP-14	56	31	
	A091304	Adv Sarc, MLN0128 v Pazopanib, Phi/II	26-JAN-15	220	79	
	A091305	HN, Adv, Thyroid PPAR agonist + Chemo	01-SEP-14	121	36	
	A091401	Sarc,	18-JUN-15	231	88	
	A091404	HN, AR+, Enzalutamide	25-SEP-15	82	41	
	EA3132	HN SCC, Stg III-IV , Adj RT +/- Cisp	29-MAR-16	0	72	
	EAQ152	Communication & education in tumor profiling	26-SEP-16	227	92	
	G0263	Cerv, Stg I/IIA, adjv RT vs chemoRT	12-APR-10	0	76	
	G0281	Ovar, Recur/prog LG, IC chemo vs trametinib	27-FEB-14	0	88	
	NRGBN001	HN, novel vs. std chemoradiation + chemo	28-AUG-15	0	98	
	NRGGY005	OVAR, Cedir vs Olaparib vs C+O vs Std of Care	06-FEB-16	321	141	
	NRGGY011	ENDO, SURG WINDOW, MPA VS MPA+ENTINOSTAT	12-APR-10	0	12	
	NRGHN001	Nasopharyngeal , Individual Tx EBV	21-APR-14	199	70	
	R0724	Cervical, Chem+RT +/- Adj. Chemo	15-JAN-14	224	93	
	R0920	HN, Adv, Postop IMRT ± Cetuximab	24-DEC-13	380	172	
	R1216	HN, Adv,Cis vs Dtx vs Dtx+Cetux	18-MAR-13	268	115	
	PREV	S0820	PACES: ColrecStg0-3 Blind DFMO/Sulindac	01-MAR-13	289	105
		A211102	Breast, Atypia via RPFNA, Metformin v Placebo	01-FEB-15	31	12
SURV	S1316	Compar. Effectiv. Trial for MBO	02-JUN-18	14	19	
	S1501	Surv, Breast Stg IV, Card Tox w/ Carvedilol	15-SEP-17	0	91	
	E1Q11	EROS: Reproductive Health in Cancer Survivors	30-SEP-15	0	43	
	EA9131	Leuk, Strategy to decrease early APL deaths	16-AUG-17	0	21	
SXQOL	A221101	Glioma, Nuvigil/Placebo Fatigue	03-JUN-13	152	64	
	NRGGU003	Pros, Post-Prostatectomy HYPOR vs COPORT	28-JUL-17	0	113	